- Global Pharma News & Resources

sk:n Clinics and Kleresca® Announce National Partnership Making the Kleresca® Biophotonic Technology Available Across the UK

sk:n Clinics and Kleresca® Announce National Partnership Making the Kleresca® Biophotonic Technology Available Across the UK

PR Newswire

STOCKHOLM, Sept. 12, 2018

STOCKHOLM, Sept. 12, 2018 /PRNewswire/ --

sk:n, the UK's leading skincare clinic group specialising in medical aesthetics and dermatology in 49 award-winning clinics and Kleresca®, an innovative Danish/Irish med-tech company focusing on fluorescent light energy in skin treatments, have announced a comprehensive partnership making the innovative biophotonic technology of Kleresca® available nationwide in the UK. 

The partnership makes gentle treatments that stimulate the skin's own healing processes with high efficacy and safety accessible to clients with both therapeutic and medical needs across the UK.

There is growing consumer appetite in the UK for non-invasive skin treatments that can be administered quickly by medical professionals yet require little to no downtime and have very few side effects.

"sk:n offer a wide range of dermatology and aesthetic treatments across our growing network of clinics. The partnership with Kleresca® further enhances our treatment portfolio with a new and innovative treatment we're confident our clients are going to love," says Lisa Mason-Poyner, Director of Medical Services at sk:n clinics.

"It is my great pleasure to announce that we have partnered with sk:n. It is an excellent platform for Kleresca® to gain a solid footing across the UK and to position our technology as the new gold standard in dermatology. The partnership offers strong support for our business," says Mikkel Shoedt, CEO of Kleresca®.

With more than 25 years of experience and over 2 million customers treated, sk:n is known for its excellent medical standards and client safety record. Practical and scientific training in Kleresca® of the sk:n nurses and practitioners commenced 1 August 2018 and 17 clinics will pilot the technology. Roll out is planned to be completed by 1 November 2018 by which the Kleresca® biophotonic treatments will be available in all 49 clinics across the UK.

The United Kingdom Health & Beauty market is forecast to grow by 21.1% over the next five years*.

* Analysis Report "The UK Health & Beauty Market 2017-2022"


Nadia Vega Vasiljev
Global PR and Communication

This information was brought to you by Cision,c2616352

The following files are available for download:


shelf for linkedin


View original content:

SOURCE Kleresca

Editor Details

  • Company:
    • PR Newswire
  • Website:
Last Updated: 12-Sep-2018